Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cellebrite DI (CLBT) Operating Income (2020 - 2025)

Historic Operating Income for Cellebrite DI (CLBT) over the last 6 years, with Q4 2025 value amounting to $20.8 million.

  • Cellebrite DI's Operating Income rose 3228.84% to $20.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $66.5 million, marking a year-over-year increase of 1682.42%. This contributed to the annual value of $66.5 million for FY2025, which is 1682.42% up from last year.
  • Cellebrite DI's Operating Income amounted to $20.8 million in Q4 2025, which was up 3228.84% from $19.0 million recorded in Q3 2025.
  • In the past 5 years, Cellebrite DI's Operating Income ranged from a high of $20.8 million in Q4 2025 and a low of -$5.6 million during Q2 2022
  • Its 5-year average for Operating Income is $9.1 million, with a median of $9.5 million in 2022.
  • As far as peak fluctuations go, Cellebrite DI's Operating Income crashed by 16810.61% in 2022, and later skyrocketed by 669926.47% in 2024.
  • Over the past 5 years, Cellebrite DI's Operating Income (Quarter) stood at $4.3 million in 2021, then soared by 124.66% to $9.7 million in 2022, then soared by 55.04% to $15.0 million in 2023, then increased by 4.85% to $15.7 million in 2024, then skyrocketed by 32.29% to $20.8 million in 2025.
  • Its last three reported values are $20.8 million in Q4 2025, $19.0 million for Q3 2025, and $14.4 million during Q2 2025.